T. Witteveen
Netherlands Cancer Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by T. Witteveen.
Acta Oncologica | 2015
D. Polders; Marcel J. Steggerda; Marcel van Herk; Kiri Nichol; T. Witteveen; L. Moonen; Jasper Nijkamp; Uulke A. van der Heide
Abstract Background. The efficacy of focal continuous low dose-rate brachytherapy (CLDR-BT) for prostate cancer requires that appropriate margins are applied to ensure robust target coverage. In this study we propose a method to establish such margins by emulating a focal treatment in patients treated with CLDR-BT to the entire gland. Material and methods. In 15 patients with localized prostate cancer, prostate volumes and dominant intra-prostatic lesions were delineated on pre-treatment magnetic resonance imaging (MRI). Delineations and MRI were registered to trans-rectal ultrasound images in the operating theater. The patients received CLDR-BT treatment to the total prostate volume. The implantation consisted of two parts: an experimental focal plan covering the dominant intra-prostatic lesion (F-GTV), followed by a plan containing additional seeds to achieve entire prostate coverage. Isodose surfaces were reconstructed using follow-up computed tomography (CT). The focal dose was emulated by reconstructing seeds from the focal plan only. The distance to agreement between planned and delivered isodose surfaces and F-GTV coverage was determined to calculate the margin required for robust treatment. Results. If patients had been treated only focally, the target volume would have been reduced from an average of 40.9 cm3 for the entire prostate to 5.8 cm3 for the focal plan. The D90 for the F-GTV in the focal plan was 195 ± 60 Gy, the V100 was 94% [range 71–100%]. The maximum distance (cd95) between the planned and delivered isodose contours was 0.48 cm. Conclusions. This study provides an estimate of 0.5 cm for the margin required for robust coverage of a focal target volume prior to actually implementing a focal treatment protocol.
Radiotherapy and Oncology | 2017
Marcel J. Steggerda; Ferrie van den Boom; T. Witteveen; L. Moonen
BACKGROUND AND PURPOSE The reliability of post-implant dosimetry in the OR depends on the geometrical variability of implant and anatomy after the procedure. The purpose was to gain detailed information on seed displacement patterns in different sectors of the prostate. MATERIALS AND METHODS Of 33 patients with stranded seed implants the seed geometry and the dose distribution were compared between the situation in the OR just after the procedure, based on ultrasound images, and the situation after 1month, based on registered CT and MR images. RESULTS There was a substantial displacement of ventral seeds of 3.8±2.5mm in caudal direction (p<0.001). Of these ventral seeds cranially located seeds moved more than caudally located seeds, 4.5±2.7mm and 2.9±2.6mm, respectively (p<0.001). The D90 in the dorsal-caudal and ventral-caudal sectors increased with respectively 44±20Gy and 29±28Gy (p<0.001) and decreased with 17±31Gy in the ventral-cranial sector (p=0.008). CONCLUSIONS There were substantial changes in dose distribution 1month after the procedure, mainly due to implant and prostate shrinkage and displacement of ventral seed strands in caudal direction. When performing dynamic dosimetry or dosimetry at the end of the procedure the effect of these phenomena has to be taken into account when using stranded seeds.
Radiotherapy and Oncology | 2013
Marcel J. Steggerda; T. Witteveen; Ferrie van den Boom; L. Moonen
Radiotherapy and Oncology | 2014
Hermine M. Dees-Ribbers; Anja Betgen; Floris J. Pos; T. Witteveen; P. Remeijer; Marcel van Herk
European Journal of Radiology | 2018
Nikolaos Grivas; K. Hinnen; Jeroen de Jong; Wilma D. Heemsbergen; L. Moonen; T. Witteveen; Henk G. van der Poel; Stijn Heijmink
Radiotherapy and Oncology | 2015
T. Witteveen; Wilma D. Heemsbergen; L. Moonen; Marcel J. Steggerda; S. Heijmink; U. Van der Heide
Radiotherapy and Oncology | 2015
Marcel J. Steggerda; F. van den Boom; T. Witteveen; L. Moonen
Radiotherapy and Oncology | 2013
D. Polders; Marcel J. Steggerda; M. van Herk; K. Nichol; T. Witteveen; L. Moonen; Jasper Nijkamp; U. Van der Heide
Radiotherapy and Oncology | 2013
Marcel J. Steggerda; T. Witteveen; F. van den Boom; L. Moonen
Radiotherapy and Oncology | 2011
Marcel J. Steggerda; T. Witteveen; H. Van Der Poel; L. Moonen